[{"indications": "Indications\u00a0immunisation against hepatitis A infection", "name": "HEPATITIS A VACCINE ", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.4 Vaccines and antisera", "Hepatitis A vaccine", "HEPATITIS A VACCINE", "Single component"], "cautions": "Cautions\u00a0see section 14.1", "side-effects": "Side-effects\u00a0see section 14.1; for\r\ncombination vaccines, see also Typhoid vaccine", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/40231.htm", "doses": ["See under preparations", "Name[Avaxim\u00ae (Sanofi Pasteur) ] Injection, suspension of formaldehyde-inactivated hepatitis A virus (GBM grown in\r\nhuman diploid cells) 320 antigen units/mL adsorbed onto aluminium\r\nhydroxide, net price 0.5-mL prefilled syringe = \u00a318.10Excipients  include neomycinDose\u00a0by intramuscular injection (see note below), adult and child over\r\n16 years, 0.5\u00a0mL as a single dose; booster dose 0.5\u00a0mL 6\u201312 months\r\nafter initial doseNote\u00a0Booster dose may be delayed by up to 3 years\r\nif not given after recommended interval following primary dose with Avaxim\u00ae. The deltoid region is the preferred site of injection.\r\nThe subcutaneous route may be used for patients with bleeding disorders;\r\nnot to be injected into the buttock (vaccine efficacy reduced)"], "pregnancy": "Pregnancy\u00a0see section 14.1"}, {"indications": "Indications\u00a0immunisation against hepatitis A infection", "name": "HEPATITIS A VACCINE  - WITH TYPHOID VACCINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.4 Vaccines and antisera", "Hepatitis A vaccine", "HEPATITIS A VACCINE", "With typhoid vaccine"], "cautions": "Cautions\u00a0see section 14.1", "side-effects": "Side-effects\u00a0see section 14.1; for\r\ncombination vaccines, see also Typhoid vaccine", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/81606.htm", "doses": ["See under preparations", "Name[Hepatyrix\u00ae (GSK) ] Injection, suspension of inactivated\r\nhepatitis A virus (grown in human diploid cells) 1440 ELISA units/mL\r\nadsorbed onto aluminium hydroxide, combined with\r\ntyphoid vaccine containing 25\u00a0micrograms/mL virulence polysaccharide\r\nantigen of Salmonella typhi, net price 1-mL prefilled\r\nsyringe = \u00a332.08Excipients  include neomycinDose\u00a0by intramuscular injection (see note below), adult and child over\r\n15 years, 1\u00a0mL as a single dose; booster doses, see under single component hepatitis A vaccine (above) and under polysaccharide typhoid vaccineNote\u00a0The deltoid region is the preferred site\r\nof injection. The subcutaneous route may be used for patients with\r\n bleeding disorders; not to be injected into the buttock (vaccine\r\nefficacy reduced)"], "pregnancy": "Pregnancy\u00a0see section 14.1"}, {"indications": "Indications\u00a0immunisation against hepatitis A infection", "name": "HEPATITIS A VACCINE  - WITH HEPATITIS B VACCINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.4 Vaccines and antisera", "Hepatitis A vaccine", "HEPATITIS A VACCINE", "With hepatitis B vaccine"], "cautions": "Cautions\u00a0see section 14.1", "side-effects": "Side-effects\u00a0see section 14.1; for\r\ncombination vaccines, see also Typhoid vaccine", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200786.htm", "doses": ["See under preparations", "Primary course should be completed with Ambirix\u00ae (single component vaccines given at appropriate\r\nintervals may be used for booster dose); the deltoid region is the\r\npreferred site of injection in older children; anterolateral thigh\r\nis the preferred site in infants; not to be injected into the buttock\r\n(vaccine efficacy reduced); subcutaneous route used for patients with\r\nbleeding disorders (but immune response may be reduced)", "Name[Ambirix\u00ae (GSK) ] Injection, suspension of inactivated\r\nhepatitis A virus (grown in human diploid cells) 720\u00a0ELISA units/mL\r\nadsorbed onto aluminium hydroxide, and recombinant (DNA) hepatitis\r\nB surface antigen (grown in yeast cells) 20\u00a0micrograms/mL adsorbed\r\nonto aluminium phosphate, net price 1-mL prefilled syringe = \u00a331.18Excipients  include neomycinDose\u00a0child 1\u201315 years, by intramuscular injection (see note below); primary course,\r\n2 doses of 1\u00a0mL, the second 6\u201312 months after initial doseNote\u00a0Primary course should be completed with Ambirix\u00ae (single component vaccines given at appropriate\r\nintervals may be used for booster dose); the deltoid region is the\r\npreferred site of injection in older children; anterolateral thigh\r\nis the preferred site in infants; not to be injected into the buttock\r\n(vaccine efficacy reduced); subcutaneous route used for patients with\r\nbleeding disorders (but immune response may be reduced)Important\u00a0Ambirix\u00ae is not recommended for post-exposure prophylaxis following\r\npercutaneous (needle-stick), ocular, or mucous membrane exposure to\r\nhepatitis B virus"], "pregnancy": "Pregnancy\u00a0see section 14.1"}, {"indications": "Indications\u00a0immunisation against hepatitis A infection", "name": "HEPATITIS A VACCINE  - SINGLE COMPONENT", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.4 Vaccines and antisera", "Hepatitis A vaccine", "HEPATITIS A VACCINE", "Single component"], "cautions": "Cautions\u00a0see section 14.1", "side-effects": "Side-effects\u00a0see section 14.1; for\r\ncombination vaccines, see also Typhoid vaccine", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/40231.htm", "doses": ["See under preparations", "Name[Avaxim\u00ae (Sanofi Pasteur) ] Injection, suspension of formaldehyde-inactivated hepatitis A virus (GBM grown in\r\nhuman diploid cells) 320 antigen units/mL adsorbed onto aluminium\r\nhydroxide, net price 0.5-mL prefilled syringe = \u00a318.10Excipients  include neomycinDose\u00a0by intramuscular injection (see note below), adult and child over\r\n16 years, 0.5\u00a0mL as a single dose; booster dose 0.5\u00a0mL 6\u201312 months\r\nafter initial doseNote\u00a0Booster dose may be delayed by up to 3 years\r\nif not given after recommended interval following primary dose with Avaxim\u00ae. The deltoid region is the preferred site of injection.\r\nThe subcutaneous route may be used for patients with bleeding disorders;\r\nnot to be injected into the buttock (vaccine efficacy reduced)"], "pregnancy": "Pregnancy\u00a0see section 14.1"}]